Georgiamune develops novel drugs by reprogramming immune signaling pathways to restore immune homeostasis. Their platform generates a broad pipeline of immunomodulators designed to activate or down-modulate the immune system. This approach targets the treatment of cancer and autoimmune diseases with high unmet need.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PIFounders
Product
Problem
Dysregulation of immune signaling pathways can lead to imbalances in the immune system, contributing to the development of cancer and autoimmune diseases. Current treatment options often lack specificity and can have broad, off-target effects, failing to restore immune homeostasis effectively. This results in significant unmet medical needs for targeted therapies that can precisely modulate immune responses.
Solution
Georgiamune is developing a pipeline of targeted immunotherapeutics designed to reprogram immune signaling pathways and restore immune homeostasis. Their approach involves creating novel drugs that can either enhance or inhibit specific immune responses, offering a more precise way to treat cancer and autoimmune diseases. By rebalancing the components of the immune system, Georgiamune aims to provide therapies that are more effective and have fewer side effects than current treatments. Their target discovery platform has generated a portfolio of first-in-class assets with the potential to address large indications with high unmet needs.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases, as well as clinicians seeking more targeted and effective immunotherapeutic options.
Features
- First-in-class immunomodulators targeting specific immune signaling pathways
- Pipeline includes both small molecule and antibody-based therapeutics
- Programs in discovery, preclinical, and IND-enabling stages
- Focus on dual-functioning molecules, Treg inhibitors, and Treg activators
- Target discovery platform fueling a robust pipeline of novel drug candidates